Products - Children and young people | Topic

Showing 27 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
Status: In developmentRemove ‘Status: In development’ filter

Diabetes (type 1 and type 2) in children and young people: diagnosis and management – periodontal disease
Status:
In development
Programme:
NICE guideline
Expected publication date:
29 June 2022
Social, emotional and mental wellbeing in primary and secondary education
Status:
In development
Programme:
NICE guideline
Expected publication date:
6 July 2022
Self harm: assessment, management and preventing recurrence
Status:
In development
Programme:
NICE guideline
Expected publication date:
6 July 2022
Urinary tract infection in under 16s: diagnosis and management
Status:
In development | In consultation
Programme:
NICE guideline
Consultation end date:
25 May 2022
Expected publication date:
27 July 2022
Otitis media with effusion in under 12s
Status:
In development
Programme:
NICE guideline
Expected publication date:
28 September 2023
Maternal and child nutrition
Status:
In development
Programme:
NICE guideline
Expected publication date:
22 November 2023
Diabetes (type 1 and type 2) in children and young people: diagnosis and management - medicines for type 2 diabetes (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
3 January 2024
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vertebral body tethering for idiopathic scoliosis in children and young people
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Somatrogon for treating growth disturbance in children and young people aged 3 and over [ID5086]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Eflornithine for maintenance treatment of high-risk neuroblastoma after 1 therapy in people up to 21 years [ID4060]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Children and young people Products

Filter

Product type
1 selected

Guidance programme

Status
1 selected

New and updated

Showing 27 products

Diabetes (type 1 and type 2) in children and young people: diagnosis and management – periodontal disease

Social, emotional and mental wellbeing in primary and secondary education

Self harm: assessment, management and preventing recurrence

Urinary tract infection in under 16s: diagnosis and management

Otitis media with effusion in under 12s

Maternal and child nutrition

Diabetes (type 1 and type 2) in children and young people: diagnosis and management - medicines for type 2 diabetes (update)

Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children

KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336

Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)

Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Omburtamab for treating relapsed neuroblastoma [ID1664]

Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]

Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]

Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]

Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]

Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Vertebral body tethering for idiopathic scoliosis in children and young people

Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]

Somatrogon for treating growth disturbance in children and young people aged 3 and over [ID5086]

Eflornithine for maintenance treatment of high-risk neuroblastoma after 1 therapy in people up to 21 years [ID4060]

Children and young people Products

Filter

Product type1 selected

Guidance programme

Status1 selected

New and updated

Showing 27 products

Product type
1 selected

Status
1 selected